Vera Therapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Vera Therapeutics, Inc. (Nasdaq: VERA) is a clinical-stage biotechnology company focused on developing and commercializing transformative biologic treatments for patients with serious immunological and rare diseases, including immunoglobulin A nephropathy (IgAN) and BK virus (BKV) infections. The company's lead product candidate is atacicept, a fully humanized TACI-Fc fusion protein that inhibits B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) to reduce autoantibody production; self-administered at home via weekly subcutaneous injection, atacicept is in late-stage development for IgAN, a progressive kidney disease, with the ORIGIN Phase 3 trial meeting its primary endpoint in June 2025. Vera also advances MAU868, a human monoclonal antibody that neutralizes BKV by blocking host cell binding for treatment of BK viremia in kidney transplant patients; and VT-109, a next-generation BAFF/APRIL dual-inhibitor under exclusive license from Stanford University with potential across B-cell mediated autoimmune diseases. Founded in 2016 and headquartered in Brisbane, California, Vera Therapeutics operates globally with full worldwide rights to its pipeline assets and targets patients with unmet needs in autoimmune kidney disorders and transplant-related complications. Recent milestones include submission of a Biologics License Application (BLA) to the U.S. FDA for atacicept in IgAN in November 2025, positioning the company for potential commercial launch in 2026; expansion of the atacicept program into additional autoimmune diseases such as lupus nephritis; receipt of FDA Breakthrough Therapy Designation in 2024; and maintenance of a strong cash position exceeding $497 million as of September 30, 2025 to support ongoing development.
Company News
Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026
Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
What's Going on With Vera Therapeutics Stock on Tuesday?
Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results
Why is Vera Therapeutics stock reversing its premarket gains?
Vera Stock Slides Despite Positive Phase 3 Results
Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics to Participate at Upcoming Investor Conferences
Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy
E. Ohman J or Asset Management AB Acquires 42,787 Shares of Vera Therapeutics, Inc. $VERA
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy Transcript
US FDA approves Vera's kidney disease drug
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy